EUVIMEDEUVIMED entdecken
Open Access

Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension

Luke J Laffin, David Rodman, James M Luther, Anand Vaidya, Matthew R Weir, Natasa Rajicic, B T Slingsby, Steven E Nissen, Target-HTN Investigators

JAMA · 26.09.2023 · 330 (12) · 1140

DOI: 10.1001/jama.2023.16029 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, erschienen am 26.09.2023. Verfasst von Luke J Laffin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cleveland Clinic Foundation, Cleveland, Ohio. Hauptthemen laut MEDLINE: Hypertension, Hypotension, Hyperaldosteronism. Die Arbeit wurde bisher 221-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Excess aldosterone production contributes to hypertension in both classical hyperaldosteronism and obesity-associated hypertension. Therapies that reduce aldosterone synthesis may lower blood pressure.

Objective

To compare the safety and efficacy of lorundrostat, an aldosterone synthase inhibitor, with placebo, and characterize dose-dependent safety and efficacy to inform dose selection in future trials. Design, Setting, and Participants Randomized, placebo-controlled, dose-ranging trial among adults with uncontrolled hypertension taking 2 or more antihypertensive medications. An initial cohort of 163 participants with suppressed plasma renin (plasma renin activity [PRA] ≤1.0 ng/mL/h) and elevated plasma aldosterone (≥1.0 ng/dL) were enrolled, with subsequent enrollment of 37 participants with PRA greater than 1.0 ng/mL/h.

Interventions

Participants were randomized to placebo or 1 of 5 dosages of lorundrostat in the initial cohort (12.5 mg, 50 mg, or 100 mg once daily or 12.5 mg or 25 mg twice daily). In the second cohort, participants were randomized in a 1:6 ratio to placebo or lorundrostat, 100 mg once daily. Main Outcomes and Measures The primary end point was change in automated office systolic blood pressure from baseline to study week 8.

Results

Between July 2021 and June 2022, 200 participants were randomized, with final follow-up in September 2022. Following 8 weeks of treatment in participants with suppressed PRA, changes in office systolic blood pressure of −14.1, −13.2, −6.9, and −4.1 mm Hg were observed with 100 mg, 50 mg, and 12.5 mg once daily of lorundrostat and placebo, respectively. Observed reductions in systolic blood pressure in individuals receiving twice-daily doses of 25 mg and 12.5 mg of lorundrostat were −10.1 and −13.8 mm Hg, respectively. The least-squares mean difference between placebo and treatment in systolic blood pressure was −9.6 mm Hg (90% CI, −15.8 to −3.4 mm Hg; P = .01) for the 50-mg once-daily dose and −7.8 mm Hg (90% CI, −14.1 to −1.5 mm Hg; P = .04) for 100 mg daily. Among participants without suppressed PRA, 100 mg once daily of lorundrostat decreased systolic blood pressure by 11.4 mm Hg (SD, 2.5 mm Hg), which was similar to blood pressure reduction among participants with suppressed PRA receiving the same dose. Six participants had increases in serum potassium above 6.0 mmol/L that corrected with dose reduction or drug discontinuation. No instances of cortisol insufficiency occurred. Conclusions and Relevance Among individuals with uncontrolled hypertension, use of lorundrostat was effective at lowering blood pressure compared with placebo, which will require further confirmatory studies. Trial Registration ClinicalTrials.gov Identifier: NCT05001945

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypertensionHypotensionHyperaldosteronismAdultHumansAldosteroneCytochrome P-450 CYP11B2ReninBlood PressureMineralocorticoid Receptor Antagonists

Substanzen

AldosteroneCytochrome P-450 CYP11B2ReninMineralocorticoid Receptor Antagonists

Autor:innen und Institutionen

  • Cleveland Clinic Foundation, Cleveland, Ohio.
  • C5 Research, Cleveland Clinic Foundation, Cleveland, Ohio.
  • Mineralys Therapeutics, Radnor, Pennsylvania.
  • Vanderbilt University Medical Center, Nashville, Tennessee.
  • Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • University of Maryland School of Medicine, Baltimore.

Zitieren

APA

Laffin, L. J., Rodman, D., Luther, J. M., Vaidya, A., Weir, M. R., Rajicic, N., Slingsby, B. T., Nissen, S. E., & Target-HTN Investigators (2023). Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension. JAMA, 330(12), 1140. https://doi.org/10.1001/jama.2023.16029

Vancouver

Laffin LJ, Rodman D, Luther JM, Vaidya A, Weir MR, Rajicic N, et al. Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension. JAMA. 2023;330(12):1140. doi:10.1001/jama.2023.16029

BibTeX
@article{Laffin2023,
  author = {Laffin, Luke J and Rodman, David and Luther, James M and Vaidya, Anand and Weir, Matthew R and Rajicic, Natasa and Slingsby, B T and Nissen, Steven E and Target-HTN Investigators, Target-HTN Investigators},
  title = {Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension},
  journal = {JAMA},
  year = {2023},
  volume = {330},
  number = {12},
  pages = {1140},
  doi = {10.1001/jama.2023.16029}
}
Kostenlos starten →